Full Press Release Details
Inspira Technologies Appointed
an Expert in the Field of Artificial Lung as the New Chief Technology Officer (CTO) - Daniella Yeheskely-Hayon PhD
Israel, February 3, 2022 - Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira
Technologies"), a groundbreaking respiratory support technology company, announced today that Daniella Yeheskely-Hayon PhD, an expert
in development of artificial lung, has been appointed as its Chief Technology Officer (CTO).
of CTO to which Yeheskely-Hayon was appointed, is a key position within the Company. As part of her role, Yeheskely-Hayon takes charge
of the research and development (R&D) department relating to its oxygenators and sensors research including its In-vitro and In-vivo
holds a PhD in Biology from the "Technion - The Israeli Institute of Technology", which is among the world's top
ten science and technology research Universities. Yeheskely-Hayon has an extensive academic work and significant peer-reviews publications
with over than 17 publications she authored.
has comprehensive project management experience in biomedical engineering as well as in key roles within medical device companies. Over
the past six years, Yeheskely-Hayon has served as the director of research and development and Chief of Operations at O2Cure
Ltd., an innovative medical device company that specializes in the development of long-term oxygenators and respiratory assist devices
Daniella Yeheskely-Hayon
Chief Technology Officer stated: " I am delighted to join the Inspira Technologies'
team and to work towards the Company's mission of becoming the new standard of care for acute respiratory patients. I believe my vast
experience in the field of blood oxygenation and Extracorporeal Membrane Oxygenation (ECMO) devices will contribute to the development
process of the Company's ART system."
Chief Executive Officer of Inspira Technologies, stated: "It is a great honor to have Daniella Yeheskely-Hayon with us as our
CTO. In the past year, Inspira Technologies has seen significant growth in its professional team. We believe that the advancement of human
resources at Inspira Technologies is a key component to achieving the Company's goals as planned."
About Inspira Technologies OXY B.H.N. Ltd.
Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART system, a cost effective
early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory
patients. The ART is designed to utilize a hemo-protective flow approach aimed at rebalancing oxygen saturation levels while patients
are awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not yet
been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or the CE or other required regulatory
more information, please visit our corporate website: www.inspirao2.com
Forward-Looking Statement
press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company
is using forward-looking statements when it discusses its goals and that Yeheskely-Hayon's experience the field of blood oxygenation
and ECMO devices will contribute to the development of the Company's ART system. These forward-looking statements and their implications
are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by
law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties
affecting the Company is contained under the heading "Risk Factors" in the Company's Registration Statement on Form
F-1 filed with the SEC, as well as its subsequent public filings, which are available on the SEC's website, www.sec.gov.
Miri Segal, Investor
Relations, MS-IR LLC, +917-607-8654, msegal@ms-ir.com